CannabisNewsBreaks

FridayJun 29, 2018 12:40 pm

CannabisNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Closes Oversubscribed Private Placement

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced the closing of its oversubscribed non-brokered private placement financing, which was previously detailed on April 9, 2018. Per the update, a total of 130,779,750 units were issued under the financing at a price of $0.05 per unit for total gross proceeds of more than $6.5 million. “I am very pleased to announce this oversubscribed placement due to investor demand in our financing and see this as a strong endorsement of the quality of our research programs and management team,” Stephen Van Deventer, chairman, CEO and…

Continue Reading

FridayJun 29, 2018 12:25 pm

CannabisNewsBreaks – Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) Actively Targets Cannabis Market in California

Vertically integrated cannabis company Sunniva’s (CSE: SNN) (OTCQX: SNNVF) core subsidiaries and licensed tenant cultivators are gearing up to supply the multibillion dollar recreational and medical cannabis industries in California. A recent article discussing the company’s unique technology reads: “Sunniva CEO Dr. Anthony Holler notes that the company has received all temporary state licenses required in California. Sunniva’s U.S. subsidiaries hold eight 10,000 square foot cultivation licenses, two manufacturing licenses, one 22,000 square foot cultivation license, one 22,000 square foot nursery license and one 10,000 square foot nursery license. Another seven 22,000 square foot cultivation bays will be leased to…

Continue Reading

FridayJun 29, 2018 9:33 am

CannabisNewsBreaks – The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Adds Prem Virmani as Chair of Beverage Science and Research Division

Cannabis-focused research and development company The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) this morning announced that Prem Virmani, former senior vice president of global science and research for Cott Beverages, Inc., has been appointed Chair of TGOD’s Beverage Science and Research Division. Per the update, Virmani has over four decades of applicable industry experience, leading development in every major category, including the Sam’s Choice cola program for Walmart, the President’s Choice cola program for Loblaws and other major private label brands for Publix, Wegmans and Safeway. “I am delighted that Prem has joined the TGOD Leadership team,”…

Continue Reading

FridayJun 29, 2018 9:27 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Files New Patent Application Following Breakthrough Discovery of Enhanced Drug Delivery to Brain Tissue

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that it has filed a new patent application with the United States Patent and Trademark Office ("USPTO") for innovation in treatment options related to central nervous system disease or disorders including viral infection, cancer, neurodegenerative disorders, ADHD, anxiety, depression, OCD, schizophrenia, Alzheimer's, Huntington's, Parkinson's, neuropathic pain and more. The company reached a breakthrough discovery during recent laboratory testing that demonstrated significantly enhanced drug delivery to brain tissue. Evidence from the study showed unexpected effectiveness in crossing the blood-brain barrier ("BBB") which Lexaria is investigating more extensively, leading to the company's…

Continue Reading

ThursdayJun 28, 2018 2:52 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Continues to Build Patent Portfolio

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is in the process of preparing new patent application filings and expects to receive more patent awards this year to add to its collection of over 40 patent awards or applications from 40 countries globally. A recent article discussing the company reads: “The total, once granted, would be four patents in the U.S. and four in Australia. All eight are for the family of “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof.” The development represents the first time that LXRP has expanded its patent protection outside of…

Continue Reading

ThursdayJun 28, 2018 11:48 am

CannabisNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Develops Innovative Therapies as Alternative Medicine Market Surges

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is developing pioneering options for preventive and curative therapies by utilizing several creative pathways. An article further discussing the company reads: “Chronic diseases and recurring health care issues are taking an increasingly bigger piece of the economic pie and disrupting the lives of many millions of people. U.S. health care costs for chronic diseases totaled $1.1 trillion in 2016 and balloon to $3.7 trillion when lost economic productivity is calculated into the total economic impact. According to a new report by Grand View Research, people around the world, along with their…

Continue Reading

ThursdayJun 28, 2018 11:39 am

CannabisNewsBreaks – Why Koios Beverage Corp. (CSE: KBEV) is “One to Watch”

Koios Beverage (CSE: KBEV) develops and distributes nature-based products such as nootropics, which are supplements that improve cognitive abilities. An article further discussing the company reads: “Not to be mistaken with prescription-only drugs which are at times used for similar effects, nootropics are over-the-counter dietary supplements; some of which, like Koios, contain ingredients that are currently used in the treatment of patients with Alzheimer’s disease. The global field of nootropics is growing rapidly and expected to reach USD $6,059.4 Mn by 2024 with a CAGR of 17.9 percent from 2016 to 2024. … According to media reports, there is believed…

Continue Reading

WednesdayJun 27, 2018 2:32 pm

CannabisNewsBreaks – Why FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) is “One to Watch”

FinCanna Capital (CSE: CALI) (OTCQB: FNNZF), a royalty company for the U.S. licensed medical cannabis industry, operates an attractive royalty model that is beneficial for operators and the company. An article further discussing the company reads: “FinCanna’s “whole capital” solution for businesses in the licensed medical cannabis sector includes the provision of capital investment for a percentage of their future revenues. The FinCanna Capital Solution utilizes a royalty arrangement to deliver capital, in order to facilitate the growth or other specific objectives of its investees, and ensure the business opportunity is optimized. This model provides an alternative or complement to…

Continue Reading

WednesdayJun 27, 2018 9:37 am

CannabisNewsBreaks – The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Enters European Market through JV Agreement in Denmark

Cannabis-focused research and development company The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) this morning announced its entry into a letter of intent for a 50/50 joint venture with Queen Genetics/Knud Jepsen A/S (“Knud Jepsen”), which is based in Hinnerup, Denmark. Per the update, the joint venture will initially consist of a 200,000 sq. ft. cannabis production facility located within Knud Jepsen’s 1.3 million sq. ft. state-of-the-art automated greenhouses in Denmark. Through this facility, TGOD will have an opportunity to increase its total organic funded capacity by roughly 25,000 kg. “We are very excited about entering the European…

Continue Reading

WednesdayJun 27, 2018 9:24 am

CannabisNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) to File IND, CTA with Health Authorities to Conduct Human Trials of PVT-005 in US and Canada

Pivot Pharmaceuticals (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning announced that it will file an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) and Clinical Trial Application (“CTA”) with Health Canada to begin human clinical trials of its pharmaceutical drug candidate for the treatment of Female Hypoactive Sexual Desire Disorder (“HSDD”), PVT-005. Pivot will employ its drug formulation and delivery platform technologies to develop a topical cream containing cannabinoids for perimenopausal, menopausal and post-menopausal women who have observed a decline in sexual desire and response. "In vitro results from our contract research laboratory indicated…

Continue Reading